We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Polydex Pharmaceuticals and Conrad, a reproductive health research organization, have halted a Phase III clinical trial of Ushercell -- a cellulose sulfate topical microbicide gel being tested for HIV prevention in women -- because preliminary results at some trial sites indicated that cellulose sulfate could lead to potential
increased risk of HIV infection in women who use the compound.
The U.S. government has gotten involved in a whistleblower suit filed in the U.S. District Court for the District of Massachusetts against Boehringer Ingelheim's generic subsidiary Roxane Laboratories alleging that Roxane violated the False Claims Act, the Department of Justice (DOJ) announced.
The Serum Institute of India and the Health Protection Agency (HPA) have announced a collaboration to develop a vaccine for the prevention of meningococcal septicaemia and meningitis.
Immtech Pharmaceuticals announced it has completed enrollment in a Phase III trial of its oral drug candidate to treat first-stage trypanosomiasis, also known as African sleeping sickness.
Argenta Discovery, a UK-based drug discovery and development
company, and AstraZeneca have announced an alliance to identify improved bronchodilators to treat chronic obstructive pulmonary disease.
The Japanese Ministry of Health, Labor and Welfare has approved Bayer Schering Pharma's long-acting intrauterine contraceptive system Mirena, the company announced.
GlaxoSmithKline (GSK) announced that its application for a new H5N1 split-antigen prepandemic influenza vaccine has been accepted for review by the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMEA).
An increase of more than 100 percent in the price of antiretroviral (ARV) drugs is likely to put the medication beyond the reach of hundreds of thousands of Zimbabweans living with HIV, the U.N.